Related Experiment Video

Updated: May 19, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Making advances in first-line chronic lymphocytic leukemia treatment

William G Wierda

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |August 8, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    Related Experiment Videos

    Last Updated: May 19, 2026

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
    09:02

    Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

    Published on: November 26, 2018

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
    06:51

    Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

    Published on: December 17, 2019

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

    Blood·2026

    Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

    Lancet (London, England)·2026

    Unfinished business in chronic lymphocytic leukemia: translational and clinical priorities for a cure.

    Blood·2026

    Developing MRD as an early endpoint for accelerated approval in CLL.

    Seminars in hematology·2026

    Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.

    Blood advances·2026

    NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

    Blood advances·2026

    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us